Biocon gets observations from EDQM for API site in Bangalore; Stock down 1%

10 Oct 2022 , 09:16 AM

Biocon Limited has notified to the stock exchanges that the European Directorate for the Quality of Medicines & HealthCare (EDQM) conducted a GMP inspection of an API manufacturing site of Biocon Limited in Bangalore.

As per the filing, the inspection was held between September 12-14, 2022 and issued a list of deficiencies on October 05, 2022. There were no critical deficiencies and one deficiency cited under the category ‘Major’.

“The company will be responding to the agency with appropriate corrective and preventive actions within the stipulated time. Biocon remains committed to the Quality, Safety & Efficacy of its products”, the company said in a regulatory filing.

On Monday early morning trade, Biocon Ltd is currently trading at Rs279.40 per share down by Rs3.35 or 1.18% from its previous closing of Rs282.75 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]